Schanbacher F L, Willett L B, Moorhead P D, Mercer H D
Environ Health Perspect. 1978 Apr;23:119-27. doi: 10.1289/ehp.7823119.
Efforts were made to more clearly delineate target organs and mechanisms of toxicity for PBBs in cattle. Methods were developed to obtain sequential liver biopsies on bovine heifers which yield 0.5 to 1.0 g of tissue. PBB was fed at a dose of 250 mg/head/day to Holstein heifers for 202 days. This dose produced no clinical signs of toxicity in any of the heifers, yet this produced tissue PBB concentration of greater than 100 times the FDA tolerance in body fat of 0.3 ppm. Liver biopsies (0.5-1.0 g each) were taken at days 0, 90, and 180. The liver tissue was homogenized and microsomes were prepared. Dithionite difference spectra were determined on the carbon monoxide treated microsome suspension and the cytochrome P-450 content determined. Also, the 100,000g supernatant was saved for ornithine decarboxylase analysis as a measure of hepatocyte proliferative activity. Results of the cytochrome P-450 analysis showed a significant (p < 0.05) two-fold elevation (per gram of wet liver) by day 90 and remained significantly (p < 0.05) elevated on day 180. The cytochrome P-450 values of control animals not receiving PBBs showed no such increase with time. The biopsy procedure appeared not to adversely affect the liver cytochrome P-450 concentration in the control heifers. These results show that PBBs at a dose of 250 mg/day induced the drug metabolism system of the liver, of which the cytochrome P-450 is a part, indicating that the liver is a potential target organ for PBBs. However, this has not been shown to cause clear signs of hepatotoxicity in the cow as determined from histopathology or serum enzyme analyses. The observed elevation of gross liver weights of the PBB-treated animals might be an expected consequence of the cytochrome P-450 induction. In contrast to rodents, the kidney has been identified by histopathology as a target organ for PBB toxicity in cattle. However, renal function studies with (131)I-sodium-iodohippurate and (125)I-sodium iodothalamate in PBB treated cows indicated that PBB toxicity to the kidney did not affect glomerular filtration rate or effective renal plasma flow even though nephrotoxic effects were produced. From these studies, both liver (as expected) and kidney (unexpected) were affected by PBBs. For liver this did not result in hepatotoxicity while for kidney nephrotoxicity was produced but could not be mechanistically explained.
人们努力更清晰地描绘多溴联苯在牛体内的靶器官和毒性机制。已开发出方法,用于对小母牛进行连续肝脏活检,每次可获取0.5至1.0克组织。以250毫克/头/天的剂量给荷斯坦小母牛喂食多溴联苯,持续202天。该剂量在任何小母牛身上均未产生毒性的临床症状,但却使组织中多溴联苯的浓度比美国食品药品监督管理局规定的0.3 ppm体脂耐受量高出100多倍。在第0天、第90天和第180天进行肝脏活检(每次0.5 - 1.0克)。将肝脏组织匀浆并制备微粒体。对经一氧化碳处理的微粒体悬浮液测定连二亚硫酸盐差异光谱,并测定细胞色素P - 450含量。此外,保留100,000克上清液用于鸟氨酸脱羧酶分析,以此作为肝细胞增殖活性的指标。细胞色素P - 450分析结果显示,到第90天(每克湿肝)显著(p < 0.05)升高两倍,在第180天仍显著(p < 0.05)升高。未接受多溴联苯的对照动物的细胞色素P - 450值未随时间出现此类增加。活检程序似乎未对对照小母牛肝脏中的细胞色素P - 450浓度产生不利影响。这些结果表明,每天250毫克的多溴联苯剂量可诱导肝脏的药物代谢系统,其中细胞色素P - 450是该系统的一部分,这表明肝脏是多溴联苯的潜在靶器官。然而,从组织病理学或血清酶分析来看,这尚未显示在奶牛身上会引发明显的肝毒性迹象。观察到的接受多溴联苯处理动物肝脏总体重量的增加可能是细胞色素P - 450诱导的预期结果。与啮齿动物不同,通过组织病理学已确定肾脏是牛体内多溴联苯毒性的靶器官。然而,对接受多溴联苯处理的奶牛进行的用(131)I - 碘马尿酸钠和(125)I - 碘肽酸钠进行的肾功能研究表明,多溴联苯对肾脏的毒性并未影响肾小球滤过率或有效肾血浆流量,尽管产生了肾毒性作用。从这些研究来看,肝脏(如预期)和肾脏(未预期)均受到多溴联苯的影响。对于肝脏,这并未导致肝毒性,而对于肾脏则产生了肾毒性,但无法从机制上进行解释。